Articles On Neuren Pharmaceuticals (ASX:NEU)

Title Source Codes Date
Neurotech reports positive top-line Phase 1/2 Rett Syndrome clinical trial results

Neurotech’s NTIRTT1 becomes first clinical trial to show statistically significant clinical improvement in Rett Syndrome patients with a broad-spectrum cannabinoid drug Company’s NTI164 compares favourably to DAYBUE, the only FDA-approved...

Stockhead NEU 1 day ago
Share tips – 8 April 2024

Share tips and stock recommendations for the Australian (ASX) share market – buy, hold, and sell. Michael Gable is an expert guest commentator for the stock market newsletter thebull.com.au. This post is an extract from the newsletter dated...

Fairmont Equities NEU 1 week ago
3 ASX shares to help turn $100,000 into $1 million

Turning $100,000 into a million bucks might sound like magic. But no one needs supernatural powers if they use ASX shares and compounding to their advantage. Allow me to introduce you to three stocks that I reckon could do the trick: Tempo...

Motley Fool NEU 2 weeks ago
Top ASX shares to buy in April 2024

If you've been a bunny and missed out on the 3.45% gains already delivered by the S&P/ASX 200 Index (ASX: XJO) so far in 2024, fear not! Because, right now is an egg-cellent time to treat yourself to some sweet new investments. But rem...

Motley Fool NEU 2 weeks ago
1 secretly cheap ASX 200 stock I'm buying for the long run

When an S&P/ASX 200 Index (ASX: XJO) stock outperforms all and sundry one year but then suddenly dips, you need to at least check out what's happening. Neuren Pharmaceuticals Ltd (ASX: NEU) was the highest climber in the ASX 200 last y...

Motley Fool NEU 3 weeks ago
3 ASX stocks boasting better margins than Nvidia

The green graphics card giant is making a motza. But did you know some ASX companies have even bigger profit margins than Nvidia Corp (NASDAQ: NVDA)? Masterfully riding the AI wave, Nvidia looks like the Kelly Slater of computer hardware....

Motley Fool NEU 3 weeks ago
The best ASX shares to invest $500 in right now

Many Australians have the impression that investing in stocks is only for rich people.  But that cannot be further from the truth. If you have just $500 you could make a pretty useful start to a portfolio. I have taken the liberty of picki...

Motley Fool NEU 4 weeks ago
Here are the top 10 ASX 200 shares today

It's been a horror end to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Friday. The ASX 200 fell sharply at market open, dropping as muc...

Motley Fool NEU 1 month ago
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 2

Morgans says more money could flow into ASX healthcare sector in 2024 as higher interest rate cycle stabilises Nyrada soars after lead drug candidate demonstrates strong efficacy in reducing secondary brain injury in animal study   Dimerix...

Stockhead NEU 1 month ago
Here are the top 10 ASX 200 shares today

The S&P/ASX 200 Index (ASX: XJO) endured another wild day of trading this Tuesday. Despite an initially strong rise this morning, investors spent most of...

Motley Fool NEU 1 month ago
$10k of savings? I'd buy these ASX 200 shares to grow my money

If you have $10,000 to invest right now, there are some excellent S&P/ASX 200 Index (ASX: XJO) stocks that can grow that money. When choosing stocks, I take the view of whether that cash will be invested in companies that will be doing...

Motley Fool NEU 1 month ago
Dr Boreham’s Crucible

Tim Boreham reports Neuren Pharmaceuticals has suffered from accusations from an activist shorter who others have debunked. By Tim Boreham ASX Code: ((NEU)) Share price: $20.16 Shares on issue: 127,234,676 Market cap: $2.56 billion Chief ex...

FNArena NEU 1 month ago
Here's the IAG dividend forecast through to 2026

The Insurance Australia Group Ltd (ASX: IAG) interim dividend announced last month was 67% higher than last year, at 10 cents per share. That's some very nice turbocharged passive income, right there. And analysts say it's only going to...

Motley Fool NEU 1 month ago
The next Neuren? Nyrada chases after two big markets – stroke and traumatic brain injury

Nyrada jumped 400pc in a single day last month The company reported good results from its Brain Injury Program Could Nyrada be the next Neuren?   Nyrada’s 400% share price rally on February 28 was the biggest single day jump of any ASX st...

Stockhead NEU 1 month ago
4 Australian shares set to soar in 2024

The S&P/ASX 200 Index (ASX: XJO) might have risen four months straight, but many experts are still bullish about the rest of 2024. Shaw and Partners portfolio manager James Gerrish said in his newsletter that his team is "bullish equit...

Motley Fool NEU 1 month ago
Leading brokers name 3 ASX shares to buy today

With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named...

Motley Fool NEU 1 month ago
FNArena Corporate Results Monitor – 04-03-2024

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AIS)) - Aeris Resources ((AUA)) - Audeara ((CMW)) - Cromwell Property ((360)) - Life360 ((NEU)) - Neuren Pharmaceuticals ((RDG)) - Resource Development Check it out at ...

FNArena NEU 1 month ago
Which ASX shares delivered the biggest profit jumps of the earnings season?

With earnings season nearing an end, we showcase 12 ASX shares that delivered some of the best profit boosts this season. In some cases, these mega profit gains led to significantly increased dividends for ASX investors, too. Which ASX s...

Motley Fool NEU 1 month ago
What's with the Neuren Pharmaceuticals share price today?

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price gained 1.1% to close at $19.36 on Thursday despite encountering some turbulence in late afternoon trading. Most of the gains occurred at the beginning of today's session with the stoc...

Motley Fool NEU 1 month ago
Neuren Pharmaceuticals reports fourth quarter royalties from DAYBUE sales

Neuren Pharmaceuticals (ASX:NEU) has reported highlights from the fourth quarter 2023 earnings announcement and its partner Acadia Pharmaceuticals' conference call.

BiotechDispatch NEU 1 month ago
Market Close: ASX200 flat as investors digest inflation data

The ASX200 closed flat despite futures having tipped a moderate green day on market as investors endeavoured to digest the Australian CPI report.  Core inflation has declined by 0.1 per cent from 4.2 to 4.1 per cent – and while that’s he...

themarketonline.com.au NEU 1 month ago
ASX Large Caps: NextDC jumps while Flight Centre and Neuren slump; Aussie inflation at two-year low

Lithium miners surge NextDC also jumps on strong H1, but Flight Centre tumbles Aussie inflation lowest in two years   The ASX 200 closed modestly lower on Wednesday with, with gains in Tech offset by losses in Comm Services and Staples se...

Stockhead NEU 1 month ago
Market Update: ASX200 flat as inflation holds at two-year low

The ASX200 has been trading quite flat. The IT sector has surged, up more than 2 per cent, while telecommunications is struggling, shedding about a per cent. The Australian Bureau of Statistics (ABS) reported a 3.4 per cent rise in in...

themarketonline.com.au NEU 1 month ago
Why Flight Centre, Fortescue, Kelsian, and Neuren shares are dropping today

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline. At the time of writing, the benchmark index is down 0.1% to 7,654.3 points. Four ASX shares that are falling more than most today are listed...

Motley Fool NEU 1 month ago
Why is this ASX 200 pharmaceuticals stock crashing 15% today?

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are crashing deep into the red today. At one stage today, the ASX 200 pharmaceuticals stock was down 15% to $18.16. Neuren's shares have recovered a touch since then but remain down by 12%. Why...

Motley Fool NEU 1 month ago
ASX Health Stocks: Neuren’s sales come in at top of guidance range, crushing short seller’s claims

  Neuren’s Daybue sales meet target Proteomics granted patent in Europe Nyrada’s brain injury drug shows efficacy in animal testing   Neuren’s Daybue sales meet target, crushing short seller’s claims Neuren Pharma (ASX:NEU) says Q4 2023 s...

Stockhead NEU 1 month ago
Neuren flags Q4 DAYBUE sales of US$87M but shares take nosedive right out the gate

Neuren has reported over US$87M in sales of DAYBUE in Q4 of 2023 The drug is sold by NASDAQ-listed Acadia in the US to treat a condition called Retts Earlier this month, short sellers claimed Acadia was lying to the market about the...

themarketonline.com.au NEU 1 month ago
Diagnosing mental disorder through sleep: How TrivarX could capture this huge research market

One in eight people in the world have some form of mental disorder TrivarX’s AI technology diagnoses mental health via sleep monitoring Stockhead reached out to TrivarX’s COO, Kai Sun   Mental health has always been a big global issue, bu...

Stockhead NEU 1 month ago
IAG shares go ex-dividend tomorrow: Should you buy now?

If you want to receive the next Insurance Australia Group Ltd (ASX: IAG) dividend, then you will have to act fast. That's because the insurance giant's shares are going ex-dividend on Wednesday. When a share trades ex-dividend, it means th...

Motley Fool NEU 1 month ago
Fundie Merchant Group picks four biotech stocks that could rip as sector hits rude health again

Biotech doesn’t need another pandemic for a resurgence – it’s made a strong comeback regardless. Stockhead spoke with Andrew Chapman, head of Perth-based fundie Merchant Group – to learn why this is the case, and which are his top picks for...

Stockhead NEU 1 month ago
Here are the top 10 ASX 200 shares today

It turned out to be a shaky, but still positive, start to the trading week for the S&P/ASX 200 Index (ASX: XJO) and most shares this Monday. By the close of trading tod...

Motley Fool NEU 1 month ago
Leading brokers name 3 ASX shares to buy today

With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named...

Motley Fool NEU 1 month ago
The Monday Report – 19 February 2024

By Greg Peel Resourceful The ASX200 shot up 76 points from the open on Friday on a combination of renewed positive sentiment over the week and a 0.5% gain on Wall Street. It then dipped and finally steadied through the afternoon to close up...

FNArena NEU 1 month ago
5 things to watch on the ASX 200 on Monday

On Friday, the S&P/ASX 200 Index (ASX: XJO) ended the week with a solid gain. The benchmark index rose 0.7% to 7,658.3 points. Will the market be able to build on this on Monday? Here are five things to watch: ASX 200 expected to edge...

Motley Fool NEU 1 month ago
A hot ASX stock with 'multiple catalysts' looming is 8% down. Time to buy

It's funny to call an ASX stock that's rocketed 217% in the past year a "bargain". But that's precisely the situation we have with Neuren Pharmaceuticals Ltd (ASX: NEU), according to the experts at Blackwattle. Let's check out their ration...

Motley Fool NEU 2 months ago
NEU ASX | Neuren Pharmaceuticals Ltd | Market Insights, News & Analysis | Livewire

Livewire NEU 2 months ago
Closing Bell: Material gains for the ASX on Friday while a good week at work sees Tech Sector gain 7.5pc

ASX adds 0.7pc to close out the week in a positive frame of mind IT and materials rise, thanks to a softening US dollar and general commodity weirdness Small caps led by NKOTB, Australian Wealth Advisors Group on a solid debut   Materi...

Stockhead NEU 2 months ago
ScoPo’s Powerplays: ASX health stocks tumble as CSL bleeds after Phase III trial misses endpoint

ASX health sector falls broader market with some key names ailing in reporting season CSL Phase III trial fails to meet primary efficacy endpoint but delivers solid H1 FY24 results Neuren Pharmaceuticals falls 13% on Friday after short sel...

Stockhead NEU 2 months ago
Brokers name 3 ASX shares to buy now

It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX sh...

Motley Fool NEU 2 months ago
The beauty of dollar cost averaging

We had a team meeting this morning. We were discussing how to make sure our readers and members were best equipped to use our advice. Spoiler: some of the people who get grumpy with our advice are those who, ahem, don't actually follow it....

Motley Fool NEU 2 months ago
“Things are worse”: Neuren Pharmaceuticals shares sink as wonder drug questioned

Neuren Pharmaceuticals (ASX:NEU) shares are tanking on news its US partner allegedly mischaracterised the safety of a drug for children The findings come from a short-selling firm That firm, Culper Research, reports the drug hospital...

themarketonline.com.au NEU 2 months ago
This ASX 200 healthcare share is diving 13% as short sellers take aim

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are ending the week deep in the red. The ASX 200 healthcare share was down 13% to $20.04 before being paused from trade. What's going on with this ASX 200 healthcare share? Investors have been h...

Motley Fool NEU 2 months ago
Here are the top 10 ASX 200 shares today

The S&P/ASX 200 Index (ASX: XJO) has just given ASX investors a not-so-merry start to December today, closing the trading week with a mild loss....

Motley Fool NEU 4 months ago
These were the best performers on the ASX 200 in November

The S&P/ASX 200 Index (ASX: XJO) was on form in November and charged higher. Over the period, the benchmark index rose 4.5% to finish the period at 7,087.3 points. While most ASX 200 shares climbed with the market, some stood out wit...

Motley Fool NEU 4 months ago
ScoPo’s Powerplays: ASX health stocks flat as a pancake but hopes still of Christmas rally

ASX health stocks flat in past five days in line with broader markets  Avita lowers full year 2023 guidance after slower progress in its customer’s VAC processes EBOS decides against acquisition of animal care business, reportedly Greencro...

Stockhead NEU 4 months ago
Allegra’s game-changing Spinal Cage device awaits FDA nod, as ASX medical device stocks make inroads

ASX medical devices to make inroads with FDA after a good year for drug developers FDA is reviewing Allegra’s Spinal Cage Device made from 3D-printed Sr-HT-Gahnite Stockhead reached out to Allegra’s board member, Dr Nick Hartnell   It’s b...

Stockhead NEU 4 months ago
Buy this ASX 200 stock for big returns after 'impressive launch'

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are having a positive start to the week. In afternoon trade, the ASX 200 pharmaceutical stock is up almost 2% to $14.93. Why is this ASX 200 stock rising? The catalyst for the rise in Neuren's s...

Motley Fool NEU 4 months ago
5 things to watch on the ASX 200 on Monday

On Friday, the S&P/ASX 200 Index (ASX: XJO) finished the week on a subdued note. The benchmark index fell 0.1% to 7,049.4 points. Will the market be able to bounce back from this on Monday? Here are five things to watch: ASX 200 expe...

Motley Fool NEU 4 months ago
ScoPo’s Powerplays: Could ASX health stocks up for third week be a start of a Christmas rally?

ASX health stocks rise in past five days and outpace broader markets for second week All study visits complete in Neuren’s Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid Syndrome Ramsay Health Care after revealing that it has reach...

Stockhead NEU 5 months ago
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead NEU 5 months ago